Study Reports Origenix Nucleotide Compounds are Effective Inhibitors of Hepatitis B Virus In Vitro

Results Reported at the 14th International Conference on Antiviral Research



Apr 10, 2001, 01:00 ET from Origenix Technologies Inc.

    MONTREAL, April 10 /PRNewswire/ -- Origenix Technologies Inc. reported
 data from an evaluation of its proprietary small molecule libraries against
 Hepatitis B virus (HBV) replication in chronic HBV-producing Human
 Hepatoblastoma cell line 2.2.15.  The study identified a number of promising
 compounds that demonstrated potent dose-dependent anti-HBV activity without
 significant cytotoxicity at very high doses.  Dr. Kris Iyer, Vice President
 and Head of Discovery Research, and Dr. Samir Mounir, Associate Director of
 Biology, presented this data at the 14th International Conference on Antiviral
 Research.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20010319/NYM025LOGO )
     Acute and Chronic liver infections caused by HBV constitute a worldwide
 public health problem with more than 1 billion people being infected.  There
 are an estimated 350 million chronic carriers of the disease worldwide, many
 of whom develop cirrhosis and hepatocellular carcinoma.
     "The data from this study is very encouraging," said Drs. Iyer, and Mounir
 "the results suggest that these compounds may exert their antiviral activities
 by inhibiting HBV DNA replication at an early step, either at, or prior to,
 the production of the first strand of HBV DNA by the HBV RT."
     "We are delighted with the results," said Doug Jensen, Origenix President
 and CEO, " the efficiency with which we were able to discover very interesting
 compounds from our "smart" molecule libraries, is added confirmation of the
 strength of our technology platform".
     Origenix has ongoing anti-viral research programs in Human Papillomavirus
 (HPV), Hepatitis B and C, Influenza, and HIV.  Its most advanced compound,
 ORI-1001, a topical antiviral agent targeting HPV, initially for the treatment
 of genital warts, is on track to enter the clinic in the second quarter of
 2001.  A follow up compound targeting a broad spectrum of HPV strains,
 including those that have been implicated in cervical and other cancers, is
 projected to enter clinical trials in 2002.
     Origenix Technologies began operations in January 1999 with headquarters
 in Laval, Quebec, and additional laboratories and office facilities in
 Worcester, Massachusetts.  The Company is engaged in the discovery and
 development of novel classes of compounds for the treatment of serious and
 life threatening diseases with the initial focus on anti-virals.  Origenix
 drug discovery platform uses an integrated approach involving the application
 of traditional medicinal chemistry and biology with advanced technologies,
 such as proprietary nucleic acid based combinatorial libraries, target based
 drug design against novel molecular targets and computational chemistry
 support.
 
     Any forward looking statements related to the Company's expectations
 regarding the performance, market acceptance, future sales and regulatory
 approval of the Company's existing and future products and potential
 arrangements with marketing partners are subject to a number of risks and
 uncertainties, many of which are beyond the Company's control.  These include,
 but are not limited to, the Company's limited capital resources, the Company's
 ability to consummate marketing partnerships on terms acceptable to it,
 unforeseen delays in or denials of FDA and other regulatory approvals, future
 product demand and pricing, performance of distributors, competitive products
 and technical developments, health care reform and general business and
 economic conditions.  There can be no assurances that the Company's
 expectations for its products will be achieved.
 
 

SOURCE Origenix Technologies Inc.
    MONTREAL, April 10 /PRNewswire/ -- Origenix Technologies Inc. reported
 data from an evaluation of its proprietary small molecule libraries against
 Hepatitis B virus (HBV) replication in chronic HBV-producing Human
 Hepatoblastoma cell line 2.2.15.  The study identified a number of promising
 compounds that demonstrated potent dose-dependent anti-HBV activity without
 significant cytotoxicity at very high doses.  Dr. Kris Iyer, Vice President
 and Head of Discovery Research, and Dr. Samir Mounir, Associate Director of
 Biology, presented this data at the 14th International Conference on Antiviral
 Research.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20010319/NYM025LOGO )
     Acute and Chronic liver infections caused by HBV constitute a worldwide
 public health problem with more than 1 billion people being infected.  There
 are an estimated 350 million chronic carriers of the disease worldwide, many
 of whom develop cirrhosis and hepatocellular carcinoma.
     "The data from this study is very encouraging," said Drs. Iyer, and Mounir
 "the results suggest that these compounds may exert their antiviral activities
 by inhibiting HBV DNA replication at an early step, either at, or prior to,
 the production of the first strand of HBV DNA by the HBV RT."
     "We are delighted with the results," said Doug Jensen, Origenix President
 and CEO, " the efficiency with which we were able to discover very interesting
 compounds from our "smart" molecule libraries, is added confirmation of the
 strength of our technology platform".
     Origenix has ongoing anti-viral research programs in Human Papillomavirus
 (HPV), Hepatitis B and C, Influenza, and HIV.  Its most advanced compound,
 ORI-1001, a topical antiviral agent targeting HPV, initially for the treatment
 of genital warts, is on track to enter the clinic in the second quarter of
 2001.  A follow up compound targeting a broad spectrum of HPV strains,
 including those that have been implicated in cervical and other cancers, is
 projected to enter clinical trials in 2002.
     Origenix Technologies began operations in January 1999 with headquarters
 in Laval, Quebec, and additional laboratories and office facilities in
 Worcester, Massachusetts.  The Company is engaged in the discovery and
 development of novel classes of compounds for the treatment of serious and
 life threatening diseases with the initial focus on anti-virals.  Origenix
 drug discovery platform uses an integrated approach involving the application
 of traditional medicinal chemistry and biology with advanced technologies,
 such as proprietary nucleic acid based combinatorial libraries, target based
 drug design against novel molecular targets and computational chemistry
 support.
 
     Any forward looking statements related to the Company's expectations
 regarding the performance, market acceptance, future sales and regulatory
 approval of the Company's existing and future products and potential
 arrangements with marketing partners are subject to a number of risks and
 uncertainties, many of which are beyond the Company's control.  These include,
 but are not limited to, the Company's limited capital resources, the Company's
 ability to consummate marketing partnerships on terms acceptable to it,
 unforeseen delays in or denials of FDA and other regulatory approvals, future
 product demand and pricing, performance of distributors, competitive products
 and technical developments, health care reform and general business and
 economic conditions.  There can be no assurances that the Company's
 expectations for its products will be achieved.
 
 SOURCE  Origenix Technologies Inc.